O xidative stress in the vascular system has been shown to be an important factor in the development of inflammation, including the inflammatory response in atherosclerosis. 1 Previous studies suggested that oxidation products of phospholipids are mediators that link oxidative stress to the development of chronic inflammation in the vascular system. 2 The oxidation of phospholipids occurs by specific enzymes or nonenzymatically by reactive oxygen species, which accumulate in inflammatory sites. 3, 4 Oxidized phospholipids are present in lipoproteins, 5 and, in addition, several reports showed that membrane lipid components of cells exposed to apoptosis, oxidative stress, and necrosis, also contain oxidized phospholipids. 5, 6 In this study we used Ox-PAPC (oxidized 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine) as a representative oxidized phospholipid. The parent molecule PAPC is an endogenous phospholipid, which is a component of both LDL and cell membrane. 7 Previously we reported that Ox-PAPC strongly activates human aortic endothelial cell (HAEC) and regulates the expression of more than 1000 genes. 8 Using microarray analysis we determined that Ox-PAPC induced multiple pathways including redox regulation (eg, heme oxygenase-1), unfolded protein response (eg, ATF3), procoagulant processes (eg, TF), sterol synthesis (eg, LDLR), and inflammation (eg, interleukin [IL]-8). Multiple, independent pathways appear to mediate the response to Ox-PAPC. For example, we previously reported that VEGF receptor 2 (VEGFR2) and NADPH oxidase 4 (NOX4) are mediators for Ox-PAPC induced expression of IL-8 but not heme oxygenase-1, 9, 10 and that the anti-inflammatory molecule HDL selectively inhibits Ox-PAPC induced IL-8 but not heme oxygenase-1 expression. We also obtained evidence that the unfolded protein response signaling regulated both basal and Ox-PAPC induced IL-8 expression in HAECs. 11 However, we did not identify the primary event(s) regulating these pathways. In this study, we focused on induction of expression of IL-8, a gene highly induced by Ox-PAPC, in order to identify the primary events by which Ox-PAPC induces inflammation. IL-8 has been demonstrated to play an important role in monocyte recruitment and retention in atherosclerosis. 12 Thus understanding the mechanism regulating IL-8 expression is important to understand the inflammatory function of Ox-PAPC.
In a previous study we used a systems genetics approach to identify genes regulated by Ox-PAPC. These studies involved microarray analysis of HAEC from 96 human donors. In the current study, to gain insight into the regulation of IL-8, we used the array data to identify genes whose expression levels showed significant correlation to IL-8 induction by Ox-PAPC. From this approach, we determined that basal expression of heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) was the most correlated gene with IL-8 induction by Ox-PAPC.
HBEGF is a ligand for the EGF receptor (EGFR) on the cell surface and requires processing by subfamily of metalloproteinase for its activation. In this report, we show that Ox-PAPC activation of specific subtypes of ADAM (a dysintegrin and metalloproteinase) leads to processing of HBEGF to an active form. We also demonstrate that, in response to Ox-PAPC, HBEGF binds to EGFR and leads to an increase of IL-8 expression in the cells. We present evidence that Ox-PAPC covalently binds to cysteine residues on ADAMs, leading to their activation. Using knockdown of one of the ADAM family members responsible for Ox-PAPC induction of IL-8, we show that this ADAM pathway may regulate at least 30% of the genes induced by Ox-PAPC. Thus, these studies combine systems genetics studies with cell biology studies to identify a novel mechanism of IL-8 regulation by Ox-PAPC in the vascular endothelium.
Methods
Further details are described in the Method section in the online-only Data Supplement.
Cell treatment
Unless otherwise indicated HAEC were changed to M199 medium containing 1% fetal bovine serum for 30 minutes before the start of the experiments. Cells were then incubated with or without Ox-PAPC in medium containing 1% serum. We used media as control treatment because the bioactive component of Ox-PAPC is fractional and unoxidized PAPC is insoluble in the reaction media. In some experiments cells were pretreated with chemical inhibitors for 1 hour and cotreated with Ox-PAPC for the indicated times.
transfection of Plasmids or sirNas
Cells were treated with plasmid or siRNA complexes with Lipofectamine 2000 (Invitrogen) for 4 hours in Opti-MEM medium (Invitrogen) and the medium was replaced with growth media. Cells were used for experiments after 2 days of cell growth. The specific silencing of target genes was confirmed by qRT-PCR and Western blotting.
adaM substrate Cleavage assay
The activity of endogenous ADAMs in HAECs or of commercial recombinant ADAM10 (Calbiochem, active form containing 215-673aa of precursor ADAM10) were determined using a fluorogenic ADAM substrate (BioMol, Dabcyl-Leu-Ala-Gln-Ala-Homophe-Arg-Ser-Lys [5-FAM]-NH 2 ). The product formation was determined by fluoroscence mesurement using excitation at 485 nm and emission at 520 nm.
Microarray data analysis
The expression levels of 22,000 transcripts after 4 hours treatment of control media and Ox-PAPC (40 μg/mL) in HAECs isolated from 96 donors were analyzed using Affymetrix HT-HU133A microarrays as previously described. 13 In a separate array analysis, to examine the effects of ADAM10 silencing in gene expression profiles, HAECs were transfected with ADAM10 siRNA as described above. After treatment of cells with control media and Ox-PAPC (40 μg/mL) for 4 hours, total RNAs were extracted from the cells to analyze the expression level of 22,000 transcripts using Affimetrix array (GeneChip Human Genome U133 Plus 2.0) in University of California at Los Angeles's microarray core facility. After data normalization using RMA using Affy R package with cutoff of FDR <0.05, the list of genes up-or downregulated by 1.5-fold by Ox-PAPC were considered as Ox-PAPC responsive genes. The genes sensitive to ADAM10 silencing were determined by more than 20% reversal of Ox-PAPC effect.
statistical analysis
Two-tailed Student t test was used to evaluate the difference between 2 groups; P<0.05 was regarded as a statistically significant.
results

iL-8 induction by Ox-PaPC is strongly Correlated With Levels of HBeGF transcript in 96 donor endothelial Cells
To find the primary events in Ox-PAPC induction of IL-8, we used data from our previously reported systems biology approach. 13 In the previous report we showed significant variation of gene expression following Ox-PAPC treatment of HAECs isolated from 150 human donors, suggesting the presence of genetic factors regulating the EC response to Ox-PAPC. For this study we analyzed genome-wide transcript profiles of a subset of HAECs isolated from 96 donors. 13 In the HAECs from different donors we found a large variation in induction of IL-8 expression by Ox-PAPC ( Figure 1 ). We confirmed a strong positive correlation of cellular IL-8 mRNA level to the IL-8 protein level in the cell supernatant using qRT-PCR and ELISA assay (data not shown). From this array data analysis we identified mRNA transcripts most correlated with the level of IL-8 induced by Ox-PAPC. The transcript across the sample population that most significantly correlated with IL-8 induction by Ox-PAPC was basal levels of IL-8 indicating a likely cis-acting regulatory element at the IL-8 locus. The second most significant was basal transcript levels of HBEGF (correlation probability value of 3.46e-09). This strongly suggested that the basal expression level of HBEGF is an important determinant in Ox-PAPC regulation of IL-8 expression in HAECs.
Ox-PaPC induction of iL-8 is regulated by HBeGF and its receptor eGF receptor
We next performed studies to validate the importance of HBEGF and its receptor EGFR in Ox-PAPC induction of IL-8 in endothelial cells. The silencing of HBEGF significantly reduced IL-8 expression in response to Ox-PAPC ( Figure 2A ). HBEGF siRNA transfection induced about 80% reduction in HAECs as determined by QRT-PCR ( Figure I . We also demonstrated that overexpression of HBEGF in HAEC increased the induction of IL-8 by Ox-PAPC ( Figure 2B ). To further determine the role of HBEGF in Ox-PAPC induced IL-8 regulation, we used HEK293 cells. HEK293 cells express EGFR but do not express HBEGF as determined by qRT-PCR (data not shown). Ox-PAPC alone does not induce IL-8 in 293 cells. However, the introduction of HBEGF into HEK293 cells caused these cells to become responsive to Ox-PAPC and showed induction of IL-8 expression ( Figure 2C ). The introduction of HBEGF expression alone without Ox-PAPC treatment did not induce IL-8 expression, suggesting that the maturation of HBEGF in response to Ox-PAPC is essential for IL-8 expression in the HEK293 cells. This indicated a mediating role of HBEGF in IL-8 induction by Ox-PAPC.
We next determined whether Ox-PAPC could increase maturation of HBEGF to the active form. Previous reports showed that formation of active HBEGF could be detected in cell lysate. 14 Ox-PAPC rapidly induced processing of precursor HBEGF (23kDa) into the active forms (8-10 kDa) in HAEC ( Figure 2D ). This processing of HBEGF happened within 10 minutes of Ox-PAPC treatment, suggesting this process to be a proximal step for IL-8 induction. There was also an increase in the total amount of HBEGF precursor in the cells in 10 to 30 minutes of Ox-PAPC treatment, possibly through enhanced translation of HBEGF in the cells. Processing may begin earlier but may not be detectable by our Western blotting method because of limited sensitivity.
As shown in Figure 2E , the commercially available recombinant HBEGF also caused a significant increase of the expression of IL-8 in HAECs although the fold induction was lower than Ox-PAPC. In array data, HBEGF was shown to be the only detectable-EGFR ligand in HAECs ( Table I in the onlineonly Data Supplement).
As shown in Figure 3A , Ox-PAPC caused a timedependent increase of IL-8 expression in HAEC, being significantly increases after 1 hour. HBEGF is a well-studied ligand of EGFR, but a role for EGFR in IL-8 induction by Ox-PAPC had not been previously reported. In this report, we demonstrated for the first time that Ox-PAPC rapidly activates EGFR in HAEC as determined by phosphorylation of Tyr 1068 of the EGFR ( Figure 3B ). Either the silencing of EGFR or an EGFR inhibitor AG1478 significantly inhibited IL-8 induction by Ox-PAPC ( Figure 3C and 3D). EGFR siRNA transfection showed 69% reduction of EGFR transcript levels in HAECs, which was confirmed by Western blotting ( Figure  IIA and IIB in the online-only Data Supplement). We confirmed the EGFR silencing effects on IL-8 expression with the reduction of IL-8 protein levels in HAECs by Western blotting and in the cell supernatants shown by IL-8 ELISA.
( Figure IIC and IID in the online-only Data Supplement). Taken together these data suggest that Ox-PAPC activates the maturation process of HBEGF in HAEC, leading to EGFR activation and IL-8 induction in the cells.
specific Metalloproteinases are Mediators of iL-8 induction by Ox-PaPC in HaeCs
It has previously been shown that EGFR signaling depends on the processing of HBEGF by ADAM, a subfamily of metalloproteinase, in various cell types but it has not been shown in endothelial cells. [15] [16] [17] [18] First, we tested the effect of metalloproteinase inhibitors on IL-8 induction by Ox-PAPC. As shown in Figure 4A , Ox-PAPC induction of IL-8 expression was inhibited by pan-metalloproteinase inhibitor GM6001. Additional metalloproteinase inhibitors including epigallocatechin gallate, phenanthroline, and EDTA showed similar inhibition effects (epigallocatechin gallate data shown in Figure III in the online-only Data Supplement). ADAM inhibitor TAPI-1 also significantly inhibited EGFR activation by Ox-PAPC in HAECs likely by inhibition of HBEGF processing on the cell surface ( Figure 4B ).
In order to identify the subtypes of ADAM that were responsible for Ox-PAPC induced IL-8 expression, we tested the effect of silencing of selected metalloproteinases expressed in HAECs. Approximately 20 subtypes of metalloproteinases are detectable in HAECs by microarray analysis ( Table II in  the online-only Data Supplement) . Among them, we tested the effects of silencing of 10 metalloproteinases that were either highly expressed or had been shown to mediate atherosclerosis by other research groups (MMP1/-2/-9, ADAM10/-15/-17/-19, ADAM-thrombospondin like domain [ADAMTS]1/-4/-9). 19, 20 From these silencing studies, as shown in Figure 4C and 4D, the ADAM10 knock-down modestly reduced basal IL-8 levels and inhibited Ox-PAPC induction of IL-8 by about 60%. ADAM19 and ADAMTS4 silencings also decreased both basal and induced levels to the same extent. Silencing of the other subtypes did not cause changes of IL-8 expression ( Figure 
Ox-PaPC increases adaM enzyme activity in HaeCs
In order to verify upregulation of ADAM activity in response to Ox-PAPC we measured the processing of fluorogenic ADAM substrate. 21 For these studies cells were incubated with Ox-PAPC for 1 hour and the substrate was added for an additional hour. As shown in Figure 5A , Ox-PAPC dosedependently increased processing of the ADAM substrate within 1 hour of treatment. The pan-metalloproteinase inhibitors (epigallocatechin gallate or TAPI-1) dose-dependently inhibited the substrate processing validating the activity measurements ( Figure VIA and VIB in the online-only Data Supplement). As an additional test of ADAM activation, HAECs were treated for 1 hour with Ox-PAPC and the processing of cellular aggrecan and release of products into the supernatant was detected ( Figure 5 ). Aggrecan is a welldefined substrate for ADAMTS family. 22 These data demonstrated the upregulation of ADAM activity by Ox-PAPC in HAECs.
Ox-PaPC interacts With Cysteine residues of adaMs
Studies from our group and others suggested that Ox-PAPC interaction with free thiols might be a mechanism by which Ox-PAPC activates ADAM enzyme. 23, 24 Previously our group reported that 1-palmitoyl-2-(5,6 epoxyisoprostanoyl)sn-glycero-3-phosphocholine (PEIPC), which is the most active lipid component in Ox-PAPC, can readily form Michael adducts with reactive cysteine on proteins. 23 For some proteins covalent binding of Ox-PAPC was observed. 23 Other groups have shown that covalent interaction of metalloproteinase with electrophiles caused enhancement of enzyme activity. 25, 26 To examine a role for this thiol interaction in ADAM activation, we first determined the ability of Ox-PAPC to covalently interact with pure recombinant ADAM10 or ADAMTS4, which are commercially available. For this purpose, we used Ox-PAPE-N-biotin, which we have previously shown to act similarly to Ox-PAPC. Recombinant enzymes were incubated with unoxidized or oxidized PAPE-N-biotin to directly detect the covalent interaction between lipids with the enzymes. After incubation covalent adducts were detected with streptavidin-HRP. As shown in Figure  5C , Ox-PAPE-N-biotin, but not unoxidized PAPE-Nbiotin, strongly interacted with recombinant ADAM10 and ADAMTS4. To determine if Ox-PAPC could covalently bind to endogenous ADAMs in cell culture, we treated cells with unoxidized or oxidized PAPE-N-biotin for 1 hour. After precipitation of biotin-labeled proteins with neutravidin-beads, we detected the presence of ADAM10 by Western blot. As shown in Figure 5D , only the oxidized form of the lipids covalently interacts with endogenous ADAM10 protein. We also detected significant covalent interactions of oxidized PAPE-N-biotin with ADAMTS4 (data not shown). We also tested the effects of p-chloromercuribenzenesulfonate, a cell-impermeable free thiol blocker, on ADAM activation by Ox-PAPC in HAECs. As shown in Figure 5E , p-chloromercuribenzenesulfonate dose-dependently inhibited the Ox-PAPC induced ADAM activity of endothelial cells, suggesting the requirement of cell surface free thiol for the ADAM activation. A cysteine analog N-acetyl-l-cysteine, which directly interacts with oxidized phospholipid, significantly inhibits ADAM enzyme activities induced by Ox-PAPC in HAECs ( Figure 5F ). In accordance with this observation, the cysteine, which has free thiol, but not cystine a disulfide form of cysteine, significantly reduced IL-8 induction by Ox-PAPC ( Figure 5G) .
We also tested a role of the p38 kinase signaling molecule in regulating ADAM activity in the cells as a previous report showed that another endogenous oxidative stress molecule, H 2 O 2 , activates ADAM via p38 in COS7 cells. 18 However, in HAECs the effect of p38 inhibitor was not observed ( Figure  VII in the online-only Data Supplement), suggesting different mechanism explains ADAM activation in the 2 cell types.
effects of adaM 10 silencing on Ox-PaPC regulation of Other Genes
In addition to the induction of IL-8 expression by Ox-PAPC, we examined the effects of ADAM10 silencing on the Ox-PAPC regulated transcriptome in HAECs using microarray analysis. In this analysis, Ox-PAPC showed upregulation of 301 genes and downregulation of 256 genes by 1.5-fold with FDR <0.05. Among these genes approximately 30% of genes exhibited ADAM10-dependent regulation (Table) . The lists and categories of these Ox-PAPC-regulated genes are shown in Tables III-X in the online-only Data Supplement. ADAM10-regulated genes are enriched in GO categories for response to cytokine stimulus, cell proliferation, and programmed cell death (Tables VI and X in the online-only Data Supplement). From this array analysis, we concluded that selective group of genes that are regulated by Ox-PAPC are ADAM10-sensitive.
discussion
We present evidence for a novel mechanism by which Ox-PAPC regulates the increased expression of the inflammatory gene IL-8 in vascular endothelial cells ( Figure 6 ). In this signaling pathway, Ox-PAPC activates specific ADAMs that process HBEGF into active form. Active HBEGF then activates EGFR, leading to IL-8 induction. This pathway is activated in less than 10 minutes of Ox-PAPC treatment, significantly before IL-8 induction is observed, suggesting that it is upstream of many of Ox-PAPC effects including IL-8 induction. The exact time course of formation of active HBEGF and the time course of EGFR activation are determined by methods that depend on sensitivity of each assay. Our study shows that both are very early events and that IL-8 induction by Ox-PAPC is heavily dependent on HBEGF. However, we cannot rule out the possibility that direct activation of EGFR may have some role in IL-8 induction. Previous reports showed that EGFR can be activated by covalent interaction with electrophiles like 4-hydroxynonenal. 27, 28 Although the role of ADAM in processing of ligands for EGFR is well defined, 20 there have previously been no reports of oxidized phospholipid activation of ADAMs. Though we have mainly focused on the effect of the ADAM-HBEGF-EGFR pathway on IL-8 induction, we also have presented evidence of a more broad importance of this pathway in induction of multiple genes by Ox-PAPC as shown in the Table. As mentioned above, a key player during EGFR transactivation process is HBEGF, which is a substrate of ADAM on the cell surface. 20 As shown in Table I in the online-only Data Supplement, the expression level of HBEGF is much higher than the other EGFR ligands in HAECs. Several groups have reported a correlation of HBEGF levels to the formation of atherosclerotic lesions. 29, 30 These observations suggest that the ADAM pathway described here is important in atherosclerosis.
Our data provide evidence for a mechanism of ADAM activation involving covalent interaction of Ox-PAPC with free thiols on ADAMs. We originally suspected that a previously reported mechanism for ADAM activation by H 2 O 2 , involving p38 activation, might also be involved. However, we saw no effect of p38 inhibition ( Figure VII in the onlineonly Data Supplement). We demonstrated that p-chloromercuribenzenesulfonate, a cell-impermeable free thiol blocker, strongly reduced ADAM activity in response to Ox-PAPC ( Figure 5E ). We previously reported that the most active lipid in Ox-PAPC for induction IL-8 is PEIPC. This lipid has an a unsaturated bond, adjacent to an epoxide bond, making it a strong electrophile for cysteine. 23 In previous microarray studies we observed that PEIPC regulates the expression of 80% of the genes regulated by Ox-PAPC. 13 We also reported that Ox-PAPC can interact with proteins via covalent modification. 23 The current study showed the direct interactions of oxidized phospholipids with recombinant or endogenous ADAM10 and ADAMTS4 ( Figure 5C HAECs were treated with Ox-PAPC (50 _g/mL) for 1 h, and the content of aggrecan fragments in the cell supernatants were determined by Western blotting using aggrecan-specific antibody. C, Oxidized phospholipids covalently interact with recombinant ADAM10 and ADAMTS4 commercially available. The active form of ADAM10 and ADAMTS4 (1 g) were incubated with unoxidized and oxidized PAPE-N-biotin (50 g/mL) for 1 h, and the SDS-PAGE separation was performed in reducing condition. The presence of biotin-labeled protein was detected by probing with streptavidin-HRP. D, Oxidized phospholipids also covalently interact with endogenous ADAM10 in HAECs. HAECs were incubated with unoxidized and oxidized PAPE-N-biotin (50 g/mL) for 1 h, and the lysates in RIPA were precipitated overnight with avidin-beads. After stringent washing with RIPA, the presence of ADAM10 biotinlabeled was detected by probing with ADAM10-specific antibody on Western blotting. E, Cell surface free thiol is required for ADAM activation by Ox-PAPC in HAECs. HAECs were pretreated with differential doses of cell surface free thiol blocker p-chloromercuribenzene sulfonate (pCMBS) for 1 h and cotreated with Ox-PAPC (50 g/mL) and fluorogenic ADAM substrate for additional 1 h, and ADAM activity was determined as described in (A). The ranges of pCMBS used in this study did not show any obvious cell damage in HAECs. F, The cysteine analog N-acetyl-L-cysteine (NAC) inhibits ADAM activation in HAECs. HAECs were pretreated with different doses of NAC for 1 h and cotreated with Ox-PAPC (50 g/mL), and ADAM activity was determined as described in (A). G, HAECs were pretreated with 200 mol/L cysteine or cystine for 1 h and cotreated with Ox-PAPC (50 g/mL) for 4 h. The mRNA levels of IL-8 were determined by qRT-PCR. Western blotting and enzyme assay were repeated at least 3 times with reproducibility and representative results were shown. The values were represented as mean value+SD, ** P<0.01, n=3 for PCR or enzyme reactions. and 5D). Furthermore, incubation of Ox-PAPC with cysteine analog blocked the effect of Ox-PAPC on ADAM activity ( Figure 5F ). Previous reports showed the presence of "cysteine switch" in the inactivating domain of some ADAMs, which prevented activation of the enzyme. 20 When this cysteine is released from the interaction with Zn ++ ion at the catalytic site, the enzyme becomes activated. The change of thiol modification of ADAM17 by oxidative stress or by thiol isomerase was shown to be a regulatory mechanism of enzyme activity. 24 The concept that Ox-PAPC can regulate metalloproteinase activity is supported by a previous report. 31 Our studies demonstrated that at least 3 ADAM proteins are involved in IL-8 induction by Ox-PAPC: ADAM10, ADAM19, and ADAMTS4 ( Figure 4C and D) . In this report, we focused on ADAM10 because its effect was most specific for Ox-PAPC. Furthermore ADAM10 has been previously shown to be involved in processing of HBEGF. 20 However, it is clear that the other ADAMs also have a strong effect on IL-8 induction. ADAMTS4 has been shown to act to breakdown matrix molecules and we demonstrated that Ox-PAPC causes the breakdown of aggrecan, a proteoglycan. 32 We hypothesize that this breakdown releases HBEGF from the matrix, contributing to the activation of EGFR. ADAM19 is important in heart development 33 and reported to be involved in the processing of neuregulin, an EGFR ligand. 34 Another group showed upregulation of ADAMTS1 in the HUVEC by Ox-PAPC treatment, 35 suggesting it may also play a role in some Ox-PAPC regulatory events.
It is now becoming clear from studies from many laboratories (including ours) that a number of receptors participate in Ox-PAPC action. These effects depend on the cell type used and the oxidized phospholipids employed. It is also clear that even within 1 cell type more than 1 receptor can be involved in a particular effect. In this article we report a role for metalloproteinase in activation of the HBEGF/EGFR axis to induce IL-8 expression. We have previously shown that VEGFR2 also plays a role in IL-8 induction. 10 Silencing of either VEGFR2 or EGFR does not cause complete inhibition of IL-8 induction by Ox-PAPC. 10 Thus these 2 receptors may have both separate and combined roles in regulating IL-8 induction and this interaction will be explored in future studies. These 2 receptors are the only ones we have shown to consistently control IL-8 induction by Ox-PAPC in HAEC.
The novel mechanism for the control of IL-8 expression reported in the current study was suggested by the results of a systems biology study from our group. This systems study examined the role of natural variation in regulating the Ox-PAPC response in HAECs. Such an approach provides a filter for the many cell signaling pathways that might have controlled IL-8 induction and highlighted an unsuspected pathway of IL-8 induction. Furthermore, the fact that this pathway correlates with a natural variation suggests its importance in human endothelial cell inflammatory responses.
In summary, as depicted in Figure 6 , we demonstrated a novel mechanism for regulation of IL-8 expression by Ox-PAPC in HAECs involving an ADAM-HBEGF-EGFR pathway. These studies highlight the potential importance of ADAM activation by Ox-PAPC as a regulator of the early events of atherosclerosis and suggest one mechanism by which ADAM may be activated involving direct binding to PEIPC or other cysteine-binding molecules in Ox-PAPC. In contrast to cancer therapy, the therapeutic application of metalloproteinase inhibitors in cardiovascular diseases has received little attention mainly because of lack of information about the role of metalloproteinase in the development of atherosclerosis. In particular, the roles of ADAM are relatively new compared *HAECs were transfected with ADAM10 siRNA for silencing. Cells were then incubated with control media or Ox-PAPC (40 µg/ml) for 4 h in triplicate. The total RNAs were isolated for microarray analysis. The 22K transcripts were analyzed using Affimetrix microarray chips as described in the Methods section. The genes upregulated or downregulated by Ox-PAPC by 1.5-fold were determined. Among these Ox-PAPC regulated genes, we identified genes that silencing of ADAM10 reversed by more than 1.2-fold. Detailed procedures and lists of the genes and gene categories are provided in both the Methods section and Tables III-X in the online-only Data Supplement. ADAM indicates a dysintegrin and metalloproteinase.
to the other types of metalloproteinases such as MMP2 and MMP9. 36 Our studies and those of others suggest that ADAMs play an important role in the development of atherosclerosis.
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